Work for Xenetic Biosciences, Inc.?
Claim Your Profile
Upgrade your company profile to unlock all of your annual report content on AnnualReports.com
Xenetic Biosciences, Inc. has reached its limit for free report views.
Upgrade your company profile to unlock all of your annual report content on AnnualReports.com
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART™ has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.
